Immunogenesis Inc.

Jul 01, 2025

ImmunoGenesis Announces the Formation of Scientific Advisory Board

May 30, 2025

ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 20, 2025

ImmunoGenesis to Present in Innovation Track of the 2025 NeauxCancer Oncology Conference in New Orleans

Mar 06, 2025

ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors